Literature DB >> 21215766

Risk assessment of coccidostatics during feed cross-contamination: animal and human health aspects.

J L C M Dorne1, M L Fernández-Cruz, U Bertelsen, D W Renshaw, K Peltonen, A Anadon, A Feil, P Sanders, P Wester, J Fink-Gremmels.   

Abstract

Coccidiosis, an intestinal plasmodium infection, is a major infectious disease in poultry and rabbits. Eleven different coccidiostats are licensed in the EU for the prevention of coccidiosis in these animal species. According to their chemical nature and main biological activity, these compounds can be grouped as ionophoric (monensin, lasalocid sodium, salinomycin, narasin, maduramicin and semduramicin) or non-ionophoric (robenidine, decoquinate, nicarbazin, diclazuril, and halofuginone) substances. Coccidiostats are used as feed additives, mixed upon request into the compounded feed. During the technical process of commercial feed production, cross-contamination of feed batches can result in the exposure of non-target animals and induce adverse health effects in these animals due to a specific sensitivity of mammalian species as compared to poultry. Residue formation in edible tissues of non-target species may result in unexpected human exposure through the consumption of animal products. This review presents recent risk assessments performed by the Scientific Panel on Contaminants in the Food Chain (CONTAM) of the European Food Safety Authority (EFSA). The health risk to non-target species that would result from the consumption of cross-contaminated feed with coccidostats at levels of 2, 5 or 10% was found to be negligible for most animal species with the exception of salinomycin and monensin in horses because of the particular sensitivity for which toxicity may occur when cross-contamination exceeds 2% and 5% respectively. Kinetic data and tissue analyses showed that residues of coccidiostats may occur in the liver and eggs in some cases. However, the level of residues of each coccidiostat in edible animal tissues remained sufficiently low that the aggregate exposure of consumers would not exceed the established acceptable daily intake (ADI) of each coccidiostat. It could be concluded that technical cross-contamination of animal feeds would not be expected to adversely affect the health of consumers.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215766     DOI: 10.1016/j.taap.2010.12.014

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  30 in total

1.  Maduramicin induces cardiac muscle cell death by the ROS-dependent PTEN/Akt-Erk1/2 signaling pathway.

Authors:  Xin Chen; Yue Li; Meng Feng; Xiaoyu Hu; Hai Zhang; Ruijie Zhang; Xiaoqing Dong; Chunxiao Liu; Zhao Zhang; Shanxiang Jiang; Shile Huang; Long Chen
Journal:  J Cell Physiol       Date:  2018-12-03       Impact factor: 6.384

2.  A preliminary study of simultaneous veterinary drug and pesticide residues in eggs produced in organic and cage-free alternative systems using LC-MS/MS.

Authors:  Mararlene Ulberg Pereira; Felipe Stanislau Cândido; Angélica Castanheira de Oliveira; Rafaela Amaral Furtado de Mendonça; Rosana Gomes Ferreira; Maria Helena Wohlers Morelli Cardoso; Lucia Helena Pinto Bastos; Bernardete Ferraz Spisso
Journal:  J Food Sci Technol       Date:  2019-12-19       Impact factor: 2.701

3.  Acute and 30-day oral toxicity studies of a novel coccidiostat - ethanamizuril.

Authors:  Wenlong Xiao; Xiaoyang Wang; Chunmei Wang; Mi Wang; Chenzhong Fei; Lifang Zhang; Feiqun Xue; Guoyong Wang; Keyu Zhang
Journal:  Toxicol Res (Camb)       Date:  2019-07-04       Impact factor: 3.524

4.  Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050.

Authors:  Maxim I Maron; Crystal T Magle; Beata Czesny; Benjamin A Turturice; Ruili Huang; Wei Zheng; Akhil B Vaidya; Kim C Williamson
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Maduramicin induces apoptosis and necrosis, and blocks autophagic flux in myocardial H9c2 cells.

Authors:  Xin Chen; Long Chen; Shanxiang Jiang; Shile Huang
Journal:  J Appl Toxicol       Date:  2017-10-19       Impact factor: 3.446

6.  Anticoccidial effect of halofuginone hydrobromide against Eimeria tenella with associated histology.

Authors:  De-Fu Zhang; Bing-Bing Sun; Ying-Ying Yue; Hai-Jie Yu; Hong-Li Zhang; Qian-Jin Zhou; Ai-Fang Du
Journal:  Parasitol Res       Date:  2012-03-14       Impact factor: 2.289

7.  Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model.

Authors:  Faezeh Koohestani; Wenan Qiang; Amy L MacNeill; Stacy A Druschitz; Vanida A Serna; Malavika Adur; Takeshi Kurita; Romana A Nowak
Journal:  Hum Reprod       Date:  2016-04-29       Impact factor: 6.918

8.  Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity.

Authors:  Sarah D'Alessandro; Yolanda Corbett; Denise P Ilboudo; Paola Misiano; Nisha Dahiya; Solomon M Abay; Annette Habluetzel; Romualdo Grande; Maria R Gismondo; Koen J Dechering; Karin M J Koolen; Robert W Sauerwein; Donatella Taramelli; Nicoletta Basilico; Silvia Parapini
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

Review 9.  Salinomycin as a drug for targeting human cancer stem cells.

Authors:  Cord Naujokat; Roman Steinhart
Journal:  J Biomed Biotechnol       Date:  2012-11-21

10.  Dose-dependent adverse effects of salinomycin on male reproductive organs and fertility in mice.

Authors:  Olajumoke Omolara Ojo; Smrati Bhadauria; Srikanta Kumar Rath
Journal:  PLoS One       Date:  2013-07-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.